Does biological agent treatment have an impact on serum uric acid levels in patients with psoriasis?

Since high serum uric acid levels have been associated with increased risk for cardiovascular diseases and metabolic syndrome, treatment of psoriasis with adalimumab, infliximab, ixekizumab, secukinumab and ustekinumab may have a positive impact on cardiometabolic comorbidities.